Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Patrick Kupelian, M.D.
Patrick Kupelian, M.D.

Specialty:

Radiation Oncology

General Information:

Gender:
Male
Language(s):
English, French, Armenian, Arabic

Affiliation(s):

Vice Chair, Radiation Oncology
Member, JCCC Cancer Molecular Imaging Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica

Education:

Fellowship:
Radiation Oncology, Cleveland Clinic Foundation, 1994 - 1996
Residency:
Radiation Oncology, University of Texas - M.D. Anderson Cancer Center, 1990 - 1994
Internship:
Rotating, American University of Beirut Medical School, 1989 - 1990
Medical Degree:
M.D., American University of Beirut Medical School, 1989

Certification(s):

Medical Board Certification(s):
Radiation Oncology, American Board of Radiology, 1995, 2004

Practice Information:

Clinical Interest(s):
Genitourinary malignancies

Scientific Interest(s):

Although Dr. Patrick Kupelian specializes in genitourinary malignancies, he an internationally known expert in the development and evaluation of cutting edge technologies in radiation oncology for a variety of anatomic sites. He has pioneered high-dose hypofractionated radiation therapy for prostate cancers and has played a significant role in the introduction and implementation of multiple image guidance techniques in radiotherapy. He has authored more than 150 research papers, more than 300 abstracts and multiple review papers and book chapters.

Selected Cancer-Related Publications:

Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012 Feb;109 Suppl 1:22-9.

Hunter GK, Reddy CA, Klein EA, Kupelian P, Angermeier K, Ulchaker J, Chehade N, Altman A, Ciezki JP. Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer. Prostate Cancer. 2012 Apr 11;2012:853487.

Santhanam AP, Min Y, Neelakkantan H, Papp N, Meeks SL, Kupelian PA. A multi-GPU real-time dose simulation software framework for lung radiotherapy. Int J Comput Assist Radiol Surg. 2012 Sep;7(5):705-19. Epub 2012 Apr 27

Tendulkar RD, Reddy CA, Stephans KL, Ciezki JP, Klein EA, Mahadevan A, Kupelian PA. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1397-404. Epub 2011 Jun 12

Kupelian P, Meyer JL. Image-guided, adaptive radiotherapy of prostate cancer: toward new standards of radiotherapy practice. Front Radiat Ther Oncol. 2011 May 20;43:344-68. Epub 2011 May 20